CO2 to Solvents with AstraZeneca

To lower product-related emissions, AstraZeneca is interested in identifying and adopting technologies capable of converting CO2 into solvents for pharmaceutical manufacturing. While AstraZeneca has begun transitioning to the use of bio-renewable solvents, these do not fully meet all the needs of production and are even at times sourced through methods that may not be considered sustainable, such as excessive use of land, water, or energy. To address these gaps, we are seeking technology partners with the potential to generate scalable solutions able to convert CO2 into organic solvents such as acetonitrile or toluene with production scale quantities, providing a more sustainable and long-term alternative. This initiative will not only address a significant portion of AstraZeneca’s carbon footprint but will also set a precedent for environmental responsibility in the industry.